Onxeo S.A.: Onxeo Announces the Transfer of the Listing of its Shares to Euronext Growth Paris on December 15, 2020
Onxeo" or "
the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, announced the transfer of the listing of its shares from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility on December 15, 2020.
The application for the admission of Onxeo's shares to the Euronext Growth market in Paris was approved by the Euronext Admissions Committee on December 9, 2020.
As a reminder, Onxeo had announced on July 29, 2010 its intention to transfer the listing of its shares to the Euronext Growth Paris multilateral trading facility. The transfer to Euronext Growth Paris is intended to enable Onxeo to be listed on a market more appropriate to the size of the company, to reduce the costs associated with listing, while enabling it to continue to benefit from the attractions of the financial markets.